$143.31
0.03% today
Nasdaq, Feb 28, 05:49 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$143.27
+18.88 15.18% 1M
+28.45 24.78% 6M
+20.12 16.34% YTD
+11.01 8.32% 1Y
+5.85 4.26% 3Y
+30.17 26.68% 5Y
-26.82 15.77% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.90 0.62%
ISIN
IE00B4Q5ZN47
Symbol
JAZZ
Sector
Industry

Key metrics

Market capitalization $8.66b
Enterprise Value $11.84b
P/E (TTM) P/E ratio 16.38
EV/FCF (TTM) EV/FCF 8.72
EV/Sales (TTM) EV/Sales 2.91
P/S ratio (TTM) P/S ratio 2.13
P/B ratio (TTM) P/B ratio 2.12
Revenue growth (TTM) Revenue growth 6.12%
Revenue (TTM) Revenue $4.07b
EBIT (operating result TTM) EBIT $726.63m
Free Cash Flow (TTM) Free Cash Flow $1.36b
Cash position $2.99b
EPS (TTM) EPS $8.75
P/E forward 13.85
P/S forward 2.01
EV/Sales forward 2.75
Short interest 9.30%
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
84%
Hold
16%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
4,069 4,069
6% 6%
100%
- Direct Costs 1,073 1,073
3% 3%
26%
2,996 2,996
7% 7%
74%
- Selling and Administrative Expenses 725 725
13% 13%
18%
- Research and Development Expense 884 884
4% 4%
22%
1,387 1,387
7% 7%
34%
- Depreciation and Amortization 660 660
3% 3%
16%
EBIT (Operating Income) EBIT 727 727
10% 10%
18%
Net Profit 560 560
35% 35%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
Seeking Alpha
2 days ago
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced per...
Neutral
Seeking Alpha
3 days ago
Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
3 days ago
– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav ® and Epidiolex ® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera ® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN...
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today